CCM
VRTX icon

Canal Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Canal Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,018
Closed -$407K – 139
2021
Q2 		$407K Sell
2,018
-5,320
-72% -$1.11M 0.12% 102
2021
Q1 		$1.58M Buy
7,338
+374
+5% +$82.1K 0.54% 59
2020
Q4 		$1.65M Buy
6,964
+1,430
+26% +$328K 0.62% 55
2020
Q3 		$1.51M Buy
+5,534
New +$1.53M 0.66% 52

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Canal Capital Management's VRTX Position: Q3 2021 in Review

Canal Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 2,018 shares — an estimated $407K sold.

Canal Capital Management first reported a position in VRTX in Q3 2020 and held it in 4 quarters. The position peaked at $1.65M in Q4 2020. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Canal Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Canal Capital Management sold 2,018 Vertex Pharmaceuticals shares in Q3 2021, an estimated $407K.
  • Canal Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Canal Capital Management's Vertex Pharmaceuticals position peaked at $1.65M in Q4 2020.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Canal Capital Management's 13F filing for Q3 2021, filed 14 Oct 2021.